Compare OLED & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | TLX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 1996 | 2024 |
| Metric | OLED | TLX |
|---|---|---|
| Price | $85.31 | $8.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $110.50 | $19.71 |
| AVG Volume (30 Days) | ★ 704.0K | 308.3K |
| Earning Date | 10-28-2026 | 02-18-2027 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | ★ 9.25 | N/A |
| EPS | ★ 3.52 | N/A |
| Revenue | ★ $650,611,000.00 | N/A |
| Revenue This Year | N/A | $16.83 |
| Revenue Next Year | $6.60 | $13.81 |
| P/E Ratio | ★ $24.16 | $150.33 |
| Revenue Growth | ★ 0.45 | N/A |
| 52 Week Low | $70.77 | $6.28 |
| 52 Week High | $134.60 | $13.11 |
| Indicator | OLED | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 37.80 |
| Support Level | $84.30 | $8.69 |
| Resistance Level | $94.98 | $9.83 |
| Average True Range (ATR) | 3.91 | 0.24 |
| MACD | -0.48 | 0.01 |
| Stochastic Oscillator | 27.12 | 1.79 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.